



29 SEPT – 2 OCT 2022
ICC BELFAST
NORTHERN IRELAND, UK

PROGRAMME

DAY 1 Thursday 29 September		Hall 1A
0900 - 1600	Pre-Conference workshops/events Registration Join OPTIONS XI	
1515 - 1600	Poster Setup	
1700 - 1710	Welcome Address: Chair, Prof. Ultan F. Power Queen's University Belfast	
1710 - 1730	Opening Keynote Early Career Investigator Award Title – tbc Dr Vahid Salimi Tehran University of Medical Sciences, Iran	
1730 - 1900	SESSION 1 – RSV Molecular Biology	
1730 - 1800	Keynote Structure and Assembly of RSV Prof. David Bhella University of Glasgow, UK	
1800 - 1815	RSV Viral Factories are Druggable Multiphasic Biocondensates Marie-Ann Rameix-Welti Université Paris-Saclay, Université de Versailles, France [ARNI0003]	
1815 - 1830	Elucidating the Role of the Pep27 Fragment in RSV Fusion Protein Function and Stability Hadley Neal University of Kentucky, USA [ARNI0119]	
1830 - 1845	Respiratory Syncytial Virus NS1 Protein Targets the Transactivator Binding Domain of MED25. Monika Bajorek INRAE, France [ARNI0009]	
1845 - 1900	Single-molecule Imaging Unravels Real-time Transcription and Replication Dynamics of RSV Dhanushika Ratnayake Hubrecht Institute, Utrecht, Netherlands [ARNI0136]	
1900 - late	Welcome Reception	
End of Day 1		

0900 - 1030	SESSION 2 – RSV Immunology – Pre-Clinical	
0900 - 0930	<p>Keynote A Novel Microbiota-host Interaction to Explain How Poor Maternal Diet Predisposes to Severe Viral Bronchiolitis A/Prof. Simon Phipps QIMR Berghofer, QLD, Australia</p>	
0930 - 0945	<p>Comparing the Cell-specific Innate Immune response to RSV between preterm and term infants An Yung Ng Murdoch Children's Research Institute, Royal Children's Hospital, Australia [ARNI0221]</p>	
0945 - 1000	<p>Presence of Neutrophils in the Lungs Prior to Infection with Respiratory Viruses Influences Disease Severity in Mice Amber Owen Imperial College London, UK [ARNI0127]</p>	
1000 - 1015	<p>Advanced modeling of RSV Infection in Neonatal Lambs Sarhad Alnajarr Lambcure LLC, USA [ARNI0029]</p>	
1015 - 1030	<p>Trans-epithelial migration is essential for neutrophil activation in the airway during RSV infection Elisabeth Robinson UCL Great Ormond Street Institute of Child Health, London, UK [ARNI0150]</p>	
1030 - 1100	<p>Refreshment break - Posters</p>	
1100-1230	SESSION 3 – RSV Vaccines and Monoclonals	
1100 - 1130	<p>Keynote Progress in the Prevention of RSV Disease: a Whirlwind Tour Prof. Ruth Karron Johns Hopkins University, USA</p>	
1130 - 1145	<p>Safety and Immunogenicity of mRNA-1345, an mRNA-Based Vaccine Against RSV in Older Adults through 6 Month Follow-up Grace L.Chen Moderna, Inc., MA, USA [ARNI0055]</p>	
1145 - 1200	<p>NIRSEVIMAB for the Prevention of RSV: Pooled Efficacy from Phase IIB and Phase III Trials in Preterm and Term Infants Eric A.F.Simoes The Children's Hospital, Aurora, USA [ARNI0139]</p>	
1200 - 1215	<p>Long term (2-year) immunogenicity of a combination Ad26.RSV.preF/RSV preF protein vaccine evaluated in a phase 1/2a study Rosemary Bastian Arangassery Janssen Vaccines and Prevention BV, Netherlands [ARNI0045]</p>	
1215 - 1230	<p>Respiratory Syncytial Virus prefusion F (RSVpreF) vaccination: antibody persistence and revaccination Edward Walsh University of Rochester, NY, USA [ARNI0243]</p>	
1230 – 1430	<p>Lunch break - Posters - Industry Symposium</p>	

1430 - 1600	SESSION 4 – Public Engagement and Question Time	
1430 – 1500	Keynote Dr Meredith McMorrow CDC, USA	
1500- 1515	Estimates of the National Burden of Respiratory Syncytial Virus in Kenyan Children Aged Under 5 years, 2010-2018 Bryan Nyawanda Kenya Medical Research Institute, Kenya	[ARNI0145]
1515 - 1530	Timing of infection with respiratory syncytial virus and risk of childhood asthma Tina Hartert Vanderbilt University Medical Center, TN, USA	[ARNI0172]
1530 - 1545	Hospitalization rates and outcomes for RSV-associated hospitalizations in adults aged 18 years and older in the United States during two respiratory seasons, October 2018 - April 2020 Fiona Havers Centers for Disease Control and Prevention, GA, USA	[ARNI0099]
1545 - 1600	Early detection and prediction of respiratory syncytial virus (RSV) outbreaks using wastewater surveillance Danielle Allen Queen's University Belfast, UK	[ARNI0168]
1600 – 1630	Refreshment break - Posters - Industry Symposium	
1630 - 1800	SESSION 5 – Public Engagement and Question Time	
1800 - 2000	Poster Session Wine Reception	
End of Day 2		
DAY 3	Saturday 1 October	Hall 1A
0900 - 1030	SESSION 6 – RSV Antivirals and Therapeutics	
0900 – 0930	Therapeutic Targeting of the RSV Polymerase Complex Keynote Prof Richard Plemper Georgia State University, Atlanta, USA	
0930 - 0945		
0945 - 1000	EDP-323, a Novel L-Protein Inhibitor, for the Treatment of Respiratory Syncytial Virus Micheal Rhodin Enanta Pharmaceuticals, MA, USA	[ARNI0028]
1000 - 1015	Immunomodulation Strategy Against Respiratory Syncytial Virus Infection by Using Lung Primocolonizing Bacteria Claire Chottin INRAE, France	[ARNI0242]

1015 - 1030	Repurposing Screen Identifies Ionafarnib as RSV Fusion Protein Inhibitor Xiaoyu Zhang Institute for Experimental Virology, Twincore, Hannover, Germany [ARNI0122]
1030 - 1100	Refreshment break - Posters
1100 - 1230	SESSION 7 – RSV Pathogenesis and Immunity in Humans
1100 – 1130	Older Age and its Impact on Infection in Adults after Human RSV Challenge Keynote Prof Chris Chiu Imperial College London, UK
1130 - 1145	Severity-Associated Transcriptional Signatures in the Respiratory Mucosa during Human Paediatric RSV Infection Megan Barnes Imperial College London, UK [ARNI0087]
1145 - 1200	Assessment of Pediatric Lung Respiratory Syncytial Virus Infection at the Single Cell Level Thomas Mariani University of Rochester, NY, USA [ARNI0178]
1200 - 1215	
1215 - 1230	Sex-Dependent Enhancement of Respiratory Syncytial Virus Infection by Toll-Like Receptor 7 Ryley McClelland University of Alberta, Canada [ARNI0190]
1230 - 1430	Lunch / industry symposium
1430 - 1630	SESSION 8 – RSV Co-infections with Other Viruses and/or Bacteria
1430 - 1500	Keynote Dr Charles Sande KEMRI – Wellcome Trust, UK
1500 - 1515	In Vitro Coinfection by Respiratory Syncytial Virus and Influenza A Virus Generates Hybrid Virions with Altered Structure and Tropism Pablo Murcia University of Glasgow, UK [ARNI0248]
1515 - 1530	Streptococcus Pneumoniae Carriage Density and Associated Respiratory Virus Coinfections in a Congregate Shelter Population in King County, WA Julia Rogers University of Washington, USA [ARNI0189]
1530 - 1545	Viral Infections and Co-infections Among American Indian and Alaska Native Children with Acute Respiratory Illness, 2019-2022 Rachel Hartman Johns Hopkins University, USA [ARNI0232]
1545 - 1600	Strong Remodeling of RSV-induced Transcriptional Signature in the Early Stages of Bacterial Superinfection in Human Airway Epithelium Justine Oliva CIRI (Centre International de Recherche en Infectiologie), France [ARNI0135]
1600 - 1630	Refreshment break - Posters
1630 - 1730	Chanock Lecture – Prof. Larry Anderson, Emory University, USA RSV Then, Now and Tomorrow, One View

1730 - 1815	Free time
1815 - 1830	<i>bus transportation from ICC to Conference Social Event</i>
1830 - late	Gala Evening at the Titanic Centre Titanic Centre Tour, Wine Reception & Gala Dinner End of Day 3
DAY 4 Sunday 2 October Hall 1A	
0930 - 1100	SESSION 9 – HMPV and Other Respiratory Viruses
0930 - 1000	Human Metapneumovirus Replication and Spread Keynote Prof. Rebecca Dutch University of Kentucky College of Medicine, USA
1000 - 1015	Human metapneumovirus lacking M2-2 protein expression accumulates defective interfering particles and hypermutated genomes that induce type-I interferon production upon infection. Kevin Groen Erasmus MC, Netherlands [ARNI0180]
1015 - 1030	Investigating The Role of HIF-1a in hMPV and RSV Infections Dorothea Morris University of Texas Medical Branch, USA [ARNI0048]
1030 - 1045	Cross-Protective Antibodies Against Common Endemic Respiratory Viruses Jim Boonyaratanakornkit Fred Hutchinson Cancer Center, WA, USA [ARNI0096]
1045 - 1100	Immunocompromised Cotton Rat Model of Human Metapneumovirus (hMPV) Infection Marina Boukhvalova Sigmovir Biosystems, Inc., USA [ARNI0174]
1100 – 1130	Refreshment break - Posters
1130 - 1300	SESSION 10 – Big Data and RSV
1130 - 1200	Using Data to Guide Policy – From Community Transmission to Vaccine Implementation Keynote: Prof. Cheryl Cohen University of Witwatersrand & Co-head NICD, S.Africa
1200 - 1215	Examining the Relationship Between Respiratory Syncytial Virus, Influenza, and Rotavirus Seasons' Timing and Severity, and Infant Age at Viral Seasons' Peaks, with Subsequent Childhood Asthma Michelle Dimitris Children's Hospital of Eastern Ontario, Canada [ARNI0056]

1215 - 1230	<p>A large-scale multi-national prospective observational cohort study documenting the summer 2021 RSV epidemic in the United Kingdom and Ireland</p> <p>Thomas Williams University of Edinburgh, UK [ARNI0059]</p>
	<p>Machine Learning in asthma: Uncovering the Link with RSV Bronchiolitis</p> <p>Keynote: Prof. Adnan Custovic Imperial College London, UK</p>
1300 - 1500	<p>Lunch / Industry Symposium</p>
1500- 1630	<p>SESSION 11 – The BIG DEBATE</p> <p><i>Our rudimentary understanding of RSV pathogenesis in humans remains a major block to developing RSV vaccines and antivirals</i></p>
1630 ->	<p>Closing Remarks</p>
<p>End of Day 4</p>	